Why the study?
Although NOACs are the first choice for stroke prevention in non-valvular AF, adherence and persistence remain suboptimal, potentially causing poor health outcomes and increased costs.
This review highlights the importance of integrated care management to improve suboptimal adherence and persistence to NOAC therapy in patients with atrial fibrillation.
May support integrated care to improve NOAC adherence in AF; leaves open efficacy on outcomes pending trials.
Atrial fibrillation (AF) is associated with an increased risk of stroke, which can be prevented by the use of oral anticoagulation. Although non-vitamin K antagonist oral anticoagulants (NOACs) have become the first choice for stroke prevention in the majority of patients with non-valvular AF, adherence and persistence to these medications remain suboptimal, which may translate into poor health outcomes and increased healthcare costs. Factors influencing adherence and persistence have been suggested to be patient-related, physician-related, and healthcare system-related. In this review, we discuss factors influencing patient adherence and persistence to NOACs and possible problem solving strategies, especially involving an integrated care management, aiming for the improvement in patient outcomes and treatment satisfaction.
No takes yet. Share an insight, caveat, or question.
Farinha et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: